Prelude Therapeutics
PRLD · Nasdaq · United States
Share price · PRLD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PRLD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 20 Aug 2026+12.5%
Nothing announced by PRLD that day or the session before.
- 11 Aug 2026+10.1%
- 28 Jul 2026+19.3%
Nothing announced by PRLD that day or the session before.
- 30 Apr 2026+22.5%
Nothing announced by PRLD that day or the session before.
- 16 Apr 2026-19.7%
- 15 Apr 2026+25.5%
- 7 Apr 2026+19.6%
Nothing announced by PRLD that day or the session before.
- 10 Mar 2026+16.5%
- 20 Feb 2026+22.5%
Nothing announced by PRLD that day or the session before.
Share of unusual movement by asset
For each asset, the share of PRLD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
PRT3789events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 4% |
| Other company news (earnings, financing, releases naming no asset) | — | 14% |
| Sessions with no dated event | — | 82% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | SMARCA2Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $5.7M | $16M | $26M+ $125M short-term inv. | $14M-$16M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $4.6M | $14M | $22M+ $60M short-term inv. | $10M-$22M operating cash flow | report ↗ |
| 2025-Q3 | $6.5M | $22M | $48M+ $7.4M short-term inv. | $20M-$19M operating cash flow | report ↗ |
| 2025-Q2 | — | $26M | $26M+ $47M short-term inv. | $31M-$26M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $29M | $40M+ $59M short-term inv. | $32M-$34M operating cash flow | report ↗ |
| 2024-Q3 | $3.0M | $29M | $11M+ $142M short-term inv. | $32M-$27M operating cash flow | report ↗ |
| 2024-Q2 | — | $30M | $28M+ $152M short-term inv. | $35M-$23M operating cash flow | report ↗ |
| 2024-Q1 | — | $27M | $25M+ $177M short-term inv. | $31M-$32M operating cash flow | report ↗ |
| 2023-Q3 | — | $26M | $16M+ $215M short-term inv. | $31M-$26M operating cash flow | report ↗ |
| 2023-Q2 | — | $25M | $26M+ $229M short-term inv. | $30M-$28M operating cash flow | report ↗ |
| 2023-Q1 | — | $22M | $18M+ $154M short-term inv. | $28M-$30M operating cash flow | report ↗ |
| 2022-Q3 | — | $23M | $52M+ $172M short-term inv. | $30M-$20M operating cash flow | report ↗ |
| 2022-Q2 | — | $21M | $51M+ $196M short-term inv. | $27M-$18M operating cash flow | report ↗ |
| 2022-Q1 | — | $23M | $52M+ $215M short-term inv. | $29M-$22M operating cash flow | report ↗ |
| 2021-Q3 | — | $23M | $61M+ $259M short-term inv. | $31M-$22M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | — | $106M | $100M | report ↗ |
Prelude Therapeutics reported full-year 2025 total revenue of $12,140 thousand, up from $7,000 thousand YoY. R&D expense was $94.3 million, down from $118.0 million YoY; cash, cash equivalents, restricted cash and marketable securities totaled $106.4 million at December 31, 2025. Net loss was $99.5 million, or $1.29 per share, versus $127.2 million, or $1.68 per share, YoY.
Management expects existing cash to fund operations into the second quarter of 2027. The FDA cleared the IND for PRT12396, a mutant-selective JAK2V617F inhibitor, with a Phase 1 study in polycythemia vera and myelofibrosis planned to begin by Q2 2026. IND-enabling studies for the KAT6A degrader PRT13722 are underway, with an IND planned for mid-2026 and Phase 1 initiation expected in H2 2026. Key events include the exclusive option agreement with Incyte for the JAK2 program, an amended and expanded DAC collaboration with AbCellera, and preclinical data presentations for the mCALR-targeted DAC discovery program.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $7.0M | $118M | $12M+ $121M short-term inv. | $32M-$103M operating cash flow | report ↗ |
| 2023-FY | — | $103M | $25M+ $208M short-term inv. | $30M-$107M operating cash flow | report ↗ |
| 2022-FY | — | $93M | $31M+ $171M short-term inv. | $29M-$84M operating cash flow | report ↗ |
| 2021-FY | — | $87M | $32M+ $259M short-term inv. | $28M-$84M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 4 purchases ($25.0M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-09 | FRIEDMAN PAUL A · director | Award / grant (derivative) | 38,000 | — | — | Form 4 |
| 2026-06-09 | Sandor Victor · director | Award / grant (derivative) | 38,000 | — | — | Form 4 |
| 2026-06-09 | Bonita David P · director, 10% owner | Award / grant (derivative) | 38,000 | — | — | Form 4 |
| 2026-06-09 | Babler Martin · director | Award / grant (derivative) | 38,000 | — | — | Form 4 |
| 2026-06-09 | Dorton Katina · director | Award / grant (derivative) | 38,000 | — | — | Form 4 |
| 2026-06-09 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Award / grant (derivative) | 38,000 | — | — | Form 4 |
| 2026-06-09 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Award / grant (derivative) | 38,000 | — | — | Form 4 |
| 2026-05-01 | Morris Charles Q · Chief Medical Officer | Award / grant (derivative) | 450,000 | $4.70 | $2.1M | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 55 reporting institutions held 30.8M shares ($103.3M, 38.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 10,909,256 | $37.3M |
| 2 | BAKER BROS. ADVISORS LP | 10,123,824 | $34.6M |
| 3 | Kynam Capital Management, LP | 1,592,551 | $5.4M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,230,406 | $4.2M |
| 5 | EcoR1 Capital, LLC | 947,049 | $3.2M |
| 6 | TWO SIGMA INVESTMENTS, LP | 923,626 | $3.2M |
| 7 | SPHERA FUNDS MANAGEMENT LTD. | 558,339 | $1.9M |
| 8 | MILLENNIUM MANAGEMENT LLC | 382,737 | $1.3M |
| 9 | MARSHALL WACE, LLP | 358,906 | $1.2M |
| 10 | MORGAN STANLEY | 322,161 | $1.1M |
| 11 | BlackRock, Inc. | 321,886 | $1.1M |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 302,458 | $1.0M |
| 13 | RENAISSANCE TECHNOLOGIES LLC | 275,200 | $941K |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 267,788 | $916K |
| 15 | GOLDMAN SACHS GROUP INC | 236,469 | $809K |